BTX Brooklyn ImmunoTherapeutics, Inc. Stock Quote

BTX [NASD]

Index	-	P/E	-	EPS (ttm)	-2.10	Insider Own	1.60%	Shs Outstand	58.80M	Perf Week	-18.04%
Market Cap	19.93M	Forward P/E	-	EPS next Y	-0.53	Insider Trans	0.00%	Shs Float	34.02M	Perf Month	-34.65%
Income	-107.50M	PEG	-	EPS next Q	-0.14	Inst Own	26.30%	Short Float	5.66%	Perf Quarter	-45.56%
Sales	-	P/S	-	EPS this Y	6.50%	Inst Trans	-18.25%	Short Ratio	3.47	Perf Half Y	-82.02%
Book/sh	0.25	P/B	1.35	EPS next Y	0.00%	ROA	-323.00%	Target Price	3.00	Perf Year	-97.14%
Cash/sh	0.33	P/C	1.03	EPS next 5Y	20.00%	ROE	-609.10%	52W Range	0.33 - 13.63	Perf YTD	-91.89%
Dividend	-	P/FCF	-	EPS past 5Y	1.60%	ROI	-	52W High	-97.58%	Beta	4.61
Dividend %	-	Quick Ratio	3.10	Sales past 5Y	-	Gross Margin	-	52W Low	0.95%	ATR	0.04
Employees	10	Current Ratio	3.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	23.51	Volatility	12.02% 9.61%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	75.60%	Profit Margin	-	Rel Volume	1.48	Prev Close	0.34
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	554.26K	Price	0.33
Recom	2.00	SMA20	-28.70%	SMA50	-36.71%	SMA200	-83.36%	Volume	172,869	Change	-2.37%

Dec-29-21

Initiated

Cantor Fitzgerald

Overweight

Oct-06-21

Initiated

Maxim Group

Buy

$20

Jul-26-22 09:49AM	Brooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer Study Benzinga -6.31%
07:30AM	Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer GlobeNewswire
Jun-17-22 05:00PM	Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency GlobeNewswire
Jun-07-22 07:30AM	Brooklyn ImmunoTherapeutics Announces Board Changes GlobeNewswire
May-31-22 07:30AM	Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting GlobeNewswire
May-27-22 04:30PM	Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q GlobeNewswire +6.79%
May-19-22 08:23AM	Amarin Announces Appointment of New Directors and Board Leadership Changes GlobeNewswire
Apr-21-22 07:30AM	Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines GlobeNewswire -5.19%
Apr-15-22 04:15PM	Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Mar-09-22 04:15PM	Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement GlobeNewswire
Mar-07-22 08:00AM	Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement GlobeNewswire
Jan-27-22 05:38PM	Cypress Point Wealth Management, LLC Buys Brooklyn ImmunoTherapeutics Inc, Robinhood Markets ... GuruFocus.com -8.82%
Jan-20-22 07:30AM	Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors GlobeNewswire -5.82%
Jan-13-22 08:30AM	Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio GlobeNewswire -6.63%
Dec-17-21 08:00AM	Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index GlobeNewswire
Dec-14-21 08:47AM	Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index GlobeNewswire
Dec-02-21 08:00AM	Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences GlobeNewswire
Nov-29-21 08:00AM	Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality GlobeNewswire
Nov-19-21 06:00AM	Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition GlobeNewswire
Nov-09-21 04:35PM	Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results GlobeNewswire
Oct-27-21 07:05AM	What Kind Of Investors Own Most Of Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX)? Simply Wall St.
Oct-14-21 04:15PM	Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq GlobeNewswire
Oct-07-21 10:11PM	Investing in These 2 Stocks Could Double Your Money, Say Analysts TipRanks
Sep-23-21 04:30PM	Brooklyn ImmunoTherapeutics Reports Inducement Grants GlobeNewswire
Sep-22-21 10:07AM	Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer GlobeNewswire
Sep-21-21 08:30AM	Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 GlobeNewswire
Sep-15-21 08:15AM	Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts PR Newswire
Sep-13-21 08:00AM	Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET GlobeNewswire
Sep-09-21 08:30AM	Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience GlobeNewswire
Aug-20-21 04:15PM	Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum GlobeNewswire +8.35%
08:30AM	Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021 GlobeNewswire
Aug-16-21 04:15PM	Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET GlobeNewswire
08:30AM	Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021 ACCESSWIRE
07:00AM	Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results GlobeNewswire
Aug-13-21 02:22PM	Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021 GlobeNewswire -5.28%
Jul-23-21 04:30PM	Brooklyn Immuno Reports Inducement Grants GlobeNewswire -14.78%
Jul-19-21 08:00AM	Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics GlobeNewswire +21.39%
Jul-13-21 08:15AM	Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer GlobeNewswire
Jul-12-21 08:15AM	Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 GlobeNewswire -5.03%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 ACCESSWIRE -5.90%
Jul-06-21 05:57PM	Brooklyn ImmunoTherapeutics Reports Inducement Grants GlobeNewswire -5.93%
Jun-14-21 07:30AM	Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics GlobeNewswire +6.43%
Jun-09-21 07:30AM	Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index GlobeNewswire
Jun-08-21 07:30AM	Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. DAmour as Chief Scientific Officer GlobeNewswire
Jun-02-21 08:00AM	Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, Massachusetts GlobeNewswire +22.07%
May-26-21 02:03PM	Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Companys Future During May 25, 2021 Shareholder Update Call Business Wire -6.68%
May-24-21 02:58PM	Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing Business Wire +21.30%
May-21-21 07:30AM	Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. Business Wire -15.57%
May-18-21 07:30AM	Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET Business Wire
May-11-21 07:30AM	Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research Business Wire -5.26%
May-07-21 07:30AM	Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics Business Wire
Apr-29-21 07:30AM	Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders Business Wire -21.75%
Apr-26-21 07:30AM	Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics Business Wire
Apr-19-21 04:10PM	Brooklyn ImmunoTherapeutics Reports Inducement Grants Business Wire
Apr-15-21 04:10PM	Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders Business Wire
08:00AM	Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc. Business Wire
Apr-06-21 08:00AM	Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc. Business Wire +29.98%
Mar-25-21 05:20PM	Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime Business Wire
Dec-14-20 08:44AM	Is the Options Market Predicting a Spike in Lineage Cell Therapeutics (LCTX) Stock? Zacks
Nov-04-20 06:05PM	Lineage Cell (LCTX) Reports Q3 Loss, Lags Revenue Estimates Zacks +6.63%
May-08-20 10:37PM	Edited Transcript of BTX earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience